News

These screens will be used for the in depth evaluation of chemical safety for human health, replacing, reducing or refining animal experiments, and improving the scientific basis of

The patent interference is related to certain pre-cooling technologies that CryoCor considers important to CryoCath’s cryoablation system. A patent interference is an administrative proceeding within the USPTO to

The approvals are for 10mg, 20mg, and 40mg dosage levels of omeprazole capsules under a mutual recognition procedure (MRP) that grants simultaneous authorizations throughout the EU. Bentley’s subsidiaries

The company is also initiating a post-approval clinical study of Orthovisc mini to gain additional clinical experience with regional opinion leaders who specialize in the treatment of osteoarthritis

The company has disclosed the activity of Arius’s anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). CD9 appears to be an important driver for leukemia and potentially other

The company expects its product to be launched in South Korea and Australia later this year. James Howard-Tripp, president and CEO, Labopharm, said: “South Korea and Australia are

Of the shares being sold, 3.22 million shares are being sold by the company and 83,000 shares are being sold by a selling stockholder. The company has granted

Eisai and Accenture Japan have reported that Accenture will provide Eisai with clinical data management services through its delivery center in Chennai. Starting full operation from February 13,

Biomoda’s non-invasive and cost-efficient screening technology identifies cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected